The use of abemaciclib and ribociclib, CDK4/6 inhibitors, with letrozole in treatment of HR-positive/HER2-negative (HR+/HER2−) breast cancer was also evaluated in India taking two scenarios into consideration [22]. This evidence concerns the gene CDK4 and breast carcinoma.